Trimetazidine，TMZ

Function:
As an additional therapy, this product is suitable for the symptomatic treatment of adult patients with stable angina pectoris who are poorly controlled or intolerable to first-line anti-angina therapy, and is only used as a second-line drug and auxiliary treatment for the treatment of angina. Note: This product is not used as a symptomatic treatment for angina pectoris, nor is it suitable for the initial treatment of unstable angina or myocardial infarction. It should not be used for treatment before admission or in the first few days after admission.

Dosage:
Trimetazidine hydrochloride tablets (capsules) are administered orally. 20mg (1 tablet/capsule) at a time, 3 times a day, take with meals. The effect will be evaluated after 3 months. If there is no therapeutic effect, the medication can be discontinued. Please follow your doctor’s advice for details. Patients with renal impairment: For patients with moderate renal impairment (creatinine clearance 30~60ml/min), the recommended dose is 20mg (1 tablet/capsule) each time, twice a day, in the morning and evening during meals. Take 1 tablet/capsule. Please follow your doctor’s advice for details. Trimetazidine hydrochloride sustained-release tablets are taken orally, 35 mg (1 tablet) twice a day, with breakfast and dinner. Patients with renal impairment: For patients with moderate renal impairment, the recommended dose is one 35 mg tablet taken daily with breakfast. Please follow your doctor’s advice for details.

Drug contraindications:
Contraindicated for children if allergic to this product Contraindicated during pregnancy Contraindicated for athletes Use with caution for those with liver and kidney dysfunction Use with caution while driving
Related dosage forms:
Trimetazidine hydrochloride tablets, trimetazidine hydrochloride capsules, trimetazidine hydrochloride sustained-release tablets